It's nice to see a detailed 4C. Despite the diminishing share price since mid-Feb there has been some great achievements in that period and the report details them well.
ALA is funded until preliminary data from Phase 1 trails and part of the focus this year is the further development of it's solid tumor products.
No red flags in this for mine.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.015(10.7%) |
Mkt cap ! $162.9M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 15.5¢ | 14.0¢ | $348.8K | 2.410M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 33333 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 161915 | 6 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| ALA (ASX) Chart |